Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jingrui Liu

Showing results (41-50 of 91) with videos related to

Pageof 10
Sort By:
Diabetes, Obesity & Metabolism|October 8, 2019
Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitusHong Zhang, Xiaoxue Zhu, Xiaojiao Li, et al.
Science Progress|February 15, 2024
Otitis media with effusion in adults during the SARS-CoV-2 epidemicYu Zhang, Feifei Yang, Yanan He, et al.
Pharmacological Research|July 26, 2022
Inulin-type fructans change the gut microbiota and prevent the development of diabetic nephropathyLiman Luo, Jinlan Luo, Yueting Cai, et al.
Expert Opinion on Investigational Drugs|December 11, 2020
Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjectsHong Zhang, Cuiyun Li, Jingrui Liu, et al.
Alimentary Pharmacology & Therapeutics|November 29, 2020
Randomised clinical trial: safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infectionHong Zhang, Yue Hu, Min Wu, et al.
Stem Cell Research|September 13, 2022
Generation of an induced pluripotent stem cell lines HMSCASTi002-A from peripheral blood mononuclear cells of a 38-year-old healthy female individualXian Xian, Jingrui Liu, Jiamin Zhang, et al.
Frontiers in Pharmacology|September 7, 2021
Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, HEC30654, in Healthy Chinese SubjectsXiaojiao Li, Lei Gao, Jingrui Liu, et al.
Journal of Clinical Laboratory Analysis|January 23, 2019
Seasonal influence on TORCH infection and analysis of multi-positive samples with indirect immunofluorescence assayLu Chen, Jingrui Liu, Lei Shi, et al.
Clinical Pharmacology in Drug Development|December 21, 2020
Pharmacokinetics and Safety of Chiglitazar, a Peroxisome Proliferator-Activated Receptor Pan-Agonist, in Patients < 65 and ≥ 65 Years With Type 2 DiabetesXiaojiao Li, Jia Yu, Min Wu, et al.
Stem Cell Research|September 16, 2022
Generation of an induced pluripotent stem cell lines HMSCASTi001-A from peripheral blood mononuclear cells of a 35-year-old healthy maleZhanchi Zhang, Jingrui Liu, Jiamin Zhang, et al.
Pageof 10

Showing results (41-50 of 91) with videos related to

Sort By:
Pageof 10
Diabetes, Obesity & Metabolism|October 8, 2019
Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitusHong Zhang, Xiaoxue Zhu, Xiaojiao Li, et al.
Science Progress|February 15, 2024
Otitis media with effusion in adults during the SARS-CoV-2 epidemicYu Zhang, Feifei Yang, Yanan He, et al.
Pharmacological Research|July 26, 2022
Inulin-type fructans change the gut microbiota and prevent the development of diabetic nephropathyLiman Luo, Jinlan Luo, Yueting Cai, et al.
Expert Opinion on Investigational Drugs|December 11, 2020
Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjectsHong Zhang, Cuiyun Li, Jingrui Liu, et al.
Alimentary Pharmacology & Therapeutics|November 29, 2020
Randomised clinical trial: safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infectionHong Zhang, Yue Hu, Min Wu, et al.
Stem Cell Research|September 13, 2022
Generation of an induced pluripotent stem cell lines HMSCASTi002-A from peripheral blood mononuclear cells of a 38-year-old healthy female individualXian Xian, Jingrui Liu, Jiamin Zhang, et al.
Frontiers in Pharmacology|September 7, 2021
Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, HEC30654, in Healthy Chinese SubjectsXiaojiao Li, Lei Gao, Jingrui Liu, et al.
Journal of Clinical Laboratory Analysis|January 23, 2019
Seasonal influence on TORCH infection and analysis of multi-positive samples with indirect immunofluorescence assayLu Chen, Jingrui Liu, Lei Shi, et al.
Clinical Pharmacology in Drug Development|December 21, 2020
Pharmacokinetics and Safety of Chiglitazar, a Peroxisome Proliferator-Activated Receptor Pan-Agonist, in Patients < 65 and ≥ 65 Years With Type 2 DiabetesXiaojiao Li, Jia Yu, Min Wu, et al.
Stem Cell Research|September 16, 2022
Generation of an induced pluripotent stem cell lines HMSCASTi001-A from peripheral blood mononuclear cells of a 35-year-old healthy maleZhanchi Zhang, Jingrui Liu, Jiamin Zhang, et al.
Pageof 10